TI
AXDX icon

tru Independence’s Accelerate Diagnostics AXDX Stock Holding History

tru Independence’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-60
Closed -$9K – 360
2020
Q2 		$9K Hold
60
– – ﹤0.01% 600
2020
Q1 		$5K Hold
60
– – ﹤0.01% 520
2019
Q4 		$5K Buy
+60
New +$9.9K ﹤0.01% 667

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

tru Independence's AXDX Position: Q3 2020 in Review

tru Independence sold out of Accelerate Diagnostics (AXDX) in Q3 2020, closing a stake of 60 shares — an estimated $9K sold.

tru Independence first reported a position in AXDX in Q4 2019 and held it in 3 quarters. The position peaked at $9K in Q2 2020. 112 funds tracked by Wall St. Rank hold AXDX as of Q3 2020.

  • tru Independence reported no remaining Accelerate Diagnostics position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 60 Accelerate Diagnostics shares in Q3 2020, an estimated $9K.
  • tru Independence first reported a position in Accelerate Diagnostics in Q4 2019 and held it in 3 quarters.
  • tru Independence's Accelerate Diagnostics position peaked at $9K in Q2 2020.
  • 112 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.